Literature DB >> 22273986

Hepatocellular carcinoma in a low-endemic area: rising incidence and improved survival.

Caroline D M Witjes1, Henrike E Karim-Kos, Otto Visser, Sanne A W van den Akker, Esther de Vries, Jan N M Ijzermans, Robert A de Man, Jan Willem W Coebergh, Cornelis Verhoef.   

Abstract

OBJECTIVE: To examine recent trends in incidence and outcome among patients with hepatocellular carcinoma (HCC) in an unselected population in Western Europe.
METHODS: Data from the nationwide Netherlands Cancer Registry were used to estimate trends in incidence for all 6514 patients newly diagnosed with primary liver cancer between 1989 and 2009. Trends in incidence, treatment, and relative survival according to sex and age were estimated in 5143 patients with HCC, also using the European Standardized Rates (ESR).
RESULTS: The ESR for all primary liver cancers combined increased significantly between 1989 and 2009 as did the ESR for HCC among men (estimated annual percentage change: 2.2%, 95% confidence interval: 1.6-2.7) and for women aged below 60 years, suggesting etiological influences in these groups. Especially, the nonhistologically confirmed HCC incidence increased. More patients underwent surgery for HCC, from 9% in 1989-1994 to 23% in 2005-2009, as well as chemotherapy and/or irradiation, from 6 to 11% in the same period. At the end of the study period, only 66% of patients received noncancer-related HCC therapy, that is, best supportive care, compared with 85% in 1989-1994. The 1 and 5-year relative survival for patients with HCC increased significantly (P<0.001 and P<0.001).
CONCLUSION: In as much as the modest increase in the incidence of HCC was a matter of better detection, due to improved imaging techniques, which may have affected the overall relative survival for HCC patients, the increasing trend in survival is likely to be, in the absence of other explanations, due to better treatment of the underlying liver cirrhosis.

Entities:  

Mesh:

Year:  2012        PMID: 22273986     DOI: 10.1097/MEG.0b013e32835030ce

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  9 in total

Review 1.  Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.

Authors:  Davide Roccarina; Avik Majumdar; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-03-10

Review 2.  Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.

Authors:  Avik Majumdar; Davide Roccarina; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-03-28

3.  Intrahepatic cholangiocarcinoma in a low endemic area: rising incidence and improved survival.

Authors:  Caroline D M Witjes; Henrike E Karim-Kos; Otto Visser; Esther de Vries; Jan N M IJzermans; Robert A de Man; Jan Willem W Coebergh; Cornelis Verhoef
Journal:  HPB (Oxford)       Date:  2012-08-17       Impact factor: 3.647

4.  Preoperative Alpha-Fetoprotein Has No Prognostic Role in Small Hepatocellular Carcinoma in Non-Cirrhotic Patients After Surgical Resection.

Authors:  Tian-Ming Gao; Dou-Sheng Bai; Jian-Jun Qian; Ping Chen; Sheng-Jie Jin; Guo-Qing Jiang
Journal:  Turk J Gastroenterol       Date:  2021-02       Impact factor: 1.852

5.  Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area.

Authors:  K Sideras; S J Bots; K Biermann; D Sprengers; W G Polak; J N M IJzermans; R A de Man; Q Pan; S Sleijfer; M J Bruno; J Kwekkeboom
Journal:  Br J Cancer       Date:  2015-06-09       Impact factor: 7.640

6.  Chalcone-Induced Apoptosis through Caspase-Dependent Intrinsic Pathways in Human Hepatocellular Carcinoma Cells.

Authors:  Rodrigo Ramirez-Tagle; Carlos A Escobar; Valentina Romero; Ignacio Montorfano; Ricardo Armisén; Vincenzo Borgna; Emanuel Jeldes; Luis Pizarro; Felipe Simon; Cesar Echeverria
Journal:  Int J Mol Sci       Date:  2016-02-22       Impact factor: 5.923

7.  Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma.

Authors:  Waled Mohsen; Marcia Rodov; Emilia Prakoso; Barbara Charlton; David G Bowen; David J Koorey; Nicholas A Shackel; Geoffrey W McCaughan; Simone I Strasser
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

8.  Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014).

Authors:  Reem Waziry; Jason Grebely; Janaki Amin; Maryam Alavi; Behzad Hajarizadeh; Jacob George; Gail V Matthews; Matthew Law; Gregory J Dore
Journal:  Hepatol Commun       Date:  2017-08-16

9.  Trends in Incidence and Mortality of Primary Liver Cancer in Lithuania 1998-2015.

Authors:  Audrius Dulskas; Povilas Kavaliauskas; Kestutis Zagminas; Ligita Jancoriene; Giedre Smailyte
Journal:  Int J Environ Res Public Health       Date:  2021-01-29       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.